A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi's Vision to Make Biologics as Affordable as Generics , /PRNewswire/ -- In a historic move reshaping global drug development, the U.S. Food and Drug Administration (FDA) today issued a formal guideline eliminating the requirement for clinical efficacy studies (CES) in biosimilar approvals, a change long championed by Professor Sarfaraz K. Niazi, Ph.D., Adjunct Professor at the University of Illinois.